Benadryl Shortage: What Providers and Prescribers Need to Know in 2026

Diphenhydramine (Benadryl) is one of the most prescribed and recommended OTC medications in clinical practice — used for allergic reactions, premedication protocols, dystonia, insomnia, and adjunct therapy in anaphylaxis. This clinical brief summarizes the 2026 availability picture, key prescribing considerations, and patient counseling guidance.

2026 Availability Summary for Clinicians

The key points for clinical settings:

Injectable diphenhydramine: The ASHP/FDA-tracked shortage that began in March 2022 was formally resolved by May 2025. Sagent Pharmaceuticals confirmed all marketed presentations are available. Formulary restrictions implemented during the shortage may be lifted at institutional discretion.

Oral diphenhydramine: No formal shortage. Multiple generic manufacturers supply the market. Tablets, capsules, liquids, and chewables are widely available in retail and hospital pharmacy settings.

Topical diphenhydramine: Cream, gel, and spray formulations available without known supply issues.

Clinical Pharmacology Refresher: Key Prescribing Points

Diphenhydramine is a first-generation H1 antihistamine and potent anticholinergic agent. It acts as an inverse agonist at peripheral and central H1 receptors, also blocking muscarinic acetylcholine receptors and sodium channels (local anesthetic effect). Key clinical pharmacology considerations:

CNS penetration: High lipophilicity allows significant BBB penetration — responsible for sedation and CNS adverse effects

Half-life: Approximately 3.4–9.3 hours; longer in elderly patients and those with hepatic impairment

Metabolism: Extensively hepatic via CYP2D6 — inhibits CYP2D6, leading to relevant drug interactions (e.g., increased thioridazine levels)

Dosing: 25–50 mg PO/IV/IM every 4–6 hours; IV administration not to exceed 25 mg/min; max 400 mg/day (parenteral)

Onset: Oral: 15–30 minutes; IV: within minutes

FDA-Approved Indications for Diphenhydramine

Allergic rhinitis (seasonal and perennial)

Allergic conjunctivitis

Mild, uncomplicated urticaria and angioedema

Adjunct to epinephrine in anaphylaxis (after acute symptoms controlled)

Motion sickness prevention and treatment

Short-term insomnia (OTC)

Parkinsonism in elderly patients unable to tolerate more potent agents

Acute dystonia reactions including torticollis and oculogyric crisis (IV/IM)

Populations Requiring Special Consideration

Elderly patients (≥65 years): Diphenhydramine is listed on the American Geriatrics Society Beers Criteria as a medication potentially inappropriate for older adults. Risks include confusion, falls, urinary retention, and associations with cognitive decline and dementia. Avoid routine use; prefer second-generation antihistamines for allergy management.

Pediatrics: Not approved for children under 2 years. Use with caution in children 2–5 (consult pediatrician). Children 6+ can take labeled doses. Paradoxical CNS stimulation is more common in pediatric patients — monitor for excitability, agitation, or insomnia.

Pregnancy/Lactation: Diphenhydramine is excreted in breast milk and crosses the placenta. Occasional use at low doses in breastfeeding is generally considered acceptable; large doses and long-term use are discouraged. Consult obstetric or lactation resources.

Hepatic impairment: Diphenhydramine is extensively metabolized by the liver. Use with caution and consider dose reduction in patients with significant hepatic impairment.

Key Drug Interactions to Counsel Patients About

Alcohol: Additive CNS depression; significantly increases impairment and sedation risk

MAO inhibitors: Prolong and intensify anticholinergic effects — avoid combination

Opioids and benzodiazepines: Additive CNS/respiratory depression — increased risk of overdose

Thioridazine: CYP2D6 inhibition by diphenhydramine increases thioridazine levels — avoid

Gabapentinoids: Increased sedation and potential respiratory depression — monitor closely

Alternative Agents to Recommend When Diphenhydramine Is Unavailable or Inappropriate

For allergic rhinitis/urticaria: Cetirizine, loratadine, fexofenadine, or levocetirizine (second/third-generation antihistamines preferred per AAAAI guidelines)

For premedication/acute allergic reactions (injectable): Hydroxyzine (PO/IM) or promethazine (IV/IM) during shortage conditions

For dystonia: Benztropine mesylate (IV/IM) as an alternative anticholinergic agent

For sleep (elderly): Low-dose doxepin, melatonin, or suvorexant as safer alternatives to diphenhydramine

How medfinder Supports Your Patients

When patients struggle to fill a prescription for diphenhydramine or any other medication, medfinder for providers offers a structured way to help. The service calls pharmacies to check stock and texts results to patients directly. See our provider guide to helping patients find Benadryl for specifics.